EFElnara Fazio-Eynullayeva

Elnara Fazio-Eynullayeva

*This is an algorithmically generated author record based on publicly available information.

Elnara Fazio-Eynullayeva has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Experiences of patient and care partner dyads in early Alzheimer’s disease: a mixed-method study in the United States

    by Lei Lv, Elnara Fazio-Eynullayeva, Paul Mystkowski, Caroline McKay, Tamara Al-Zubeidi, Jordan Miller, Stephanie McKee, Catherine Bottomley, Catherine Floegel, Richard Hyde, et al.

    Understanding the holistic experience of patients with early Alzheimer's disease (AD) and their care partners is important to identify unmet needs. This study aimed to describe and compare patient-care partner dyad experiences and perspectives in early AD. Experiences of patients and their care partners (dyads) were explored using a survey, qualitative interviews, and social media listening. Each dyad completed a 25-minute quantitative online survey exploring their perceptions of symptoms, comorbidity impact, financial burden, and preferred treatment characteristics. Data were analyzed descriptively and comparatively. 150 patient-care partner dyads completed the survey. Patients and care partners frequently reported memory-related issues and cognitive challenges (68% and 77%, respectively); approximately 19% of responses were discordant, with patients often under-reporting symptoms. Managing comorbidities worsened overall well-being of patients (41%) and care partners (40%). Treatments slowing AD progression (patients: 99%; care partners: 96%) and improving symptoms (patients: 95%; care partners: 93%) were important. Approximately 26% of respondents experienced significant negative financial impacts. Patients and care partners perceived early AD impacts similarly whereas some symptoms were perceived differently. There was a shared desire for disease-modifying treatments. Limited financial impact may reflect preserved functionality and limited use of disease-modifying treatments.


  • Open Access

    A Real-World Analysis of the Clinical Journey, Diagnosis, and Monitoring Patterns of Patients With Alzheimer Disease by Stage in the United States

    by Elnara Fazio-Eynullayeva, Paul Mystkowski, Lei Lv, Abdalla Aly, Sarah Cotton, Nikisha Grant, Will Johnson, Soeren Mattke

    This study aimed to describe the clinical journey of patients with different stages of Alzheimer disease (AD). This was a cross-sectional survey of US primary care physicians (PCPs)/specialists and patients using the Adelphi Real World AD Disease Specific Programme™ (December 2022 – September 2023). Patients were stratified by disease severity and data are presented as the mean (SD) or frequencies/percentages. In the overall sample ( N = 990), mean time from symptom onset to first evaluation was 31.4 (40.6) weeks and mean time from evaluation to diagnosis was 14.2 (29.0) weeks (mild cognitive impairment due to AD, 12.0 [22.7] weeks; mild AD dementia, 15.7 [31.6] weeks; moderate AD dementia, 14.0 [29.9] weeks; severe AD dementia, 5.1 [9.6] weeks). 74.5% of the overall sample was initially evaluated by their PCP and 13.8% by a neurologist. Patients with AD experience many barriers during the diagnostic journey; however, PCPs and neurologists play key roles in early diagnosis.


  • Open Access

    Real-world healthcare resource utilization of Alzheimer’s disease in the early and advanced stages: a retrospective cohort study

    by Elnara Fazio-Eynullayeva, Marianne Cunnington, Paul Mystkowski, Lei Lv, Abdalla Aly, Christopher W. Yee, Raj Desai, Chia-Lun Liu, Mei Sheng Duh, Soeren Mattke

    AimsTo compare all-cause and Alzheimer's disease (AD)-related healthcare resource utilization (HCRU) by cognitive stage.Methods and MaterialsThis retrospective study analyzed insurance claims data linked to electronic health records (01/01/2015-12/31/2021). Patients with ≥1 cognitive assessment (Mini-Mental State Examination or Montreal Cognitive Assessment) and ≥1 medical or pharmacy claim for an AD diagnosis or AD medications were included. Inverse probability of treatment weighting (IPTW) was used to address potential confounding. All-cause and AD-related HCRU were summarized per patient per year (PPPY) and compared between early AD and advanced AD cohorts (defined according to cognitive scores) using generalized linear regression models; adjusted incidence rate ratios (IRRs), and 95% confidence intervals (CI) were reported.ResultsA total of 193 patients were included (median age: 82 years; 63.2% female), 108 with early AD and 85 with advanced AD, with similar mean follow up. All-cause HCRU, on average, was similar between early AD and advanced AD cohorts (37.4 PPPY and 38.9 encounters PPPY, respectively). For AD-related HCRU, patients with early AD had fewer encounters PPPY, on average, than patients with advanced AD (1.26 and 3.88 encounters, respectively). Following IPTW adjustment, the advanced AD cohort had significantly higher overall AD-related HCRU (IRR: 3.64 [95% CI: 1.96-6.75], p <0.001) and outpatient visits (IRR: 2.76 [95% CI: 1.68-4.54], p <0.001) compared to the early AD cohort.LimitationsThe relatively small sample size of patients with linked claims and cognitive score data limited the ability to assess contribution of all encounter types to HCRU trends, as well as generalizability to the broader AD population.ConclusionsAlthough all-cause HCRU was similar, patients with advanced AD incurred higher AD-related HCRU compared to patients living with early AD. Further research is needed to determine whether interventions earlier in disease progression can mitigate the AD-related healthcare burden for patients with advanced AD.


  • Open Access

    Evolving Effect of the COVID-19 Pandemic on Cancer-Related Encounters

    by Jack W. London, Elnara Fazio-Eynullayeva, Matvey B. Palchuk, Christopher McNair

    PURPOSE: This is an update to a previously published report characterizing the impact that efforts to control the COVID-19 pandemic have had on the normal course of cancer-related encounters. METHODS: Data were analyzed from 22 US health care organizations (members of the TriNetX global network) having relevant, up-to-date encounter data. Although the original study compared encounter data pre–COVID-19 (January-April 2019) with the corresponding months in 2020, this update considers data through April 2021. As before, cohorts were generated for all neoplasm patients (malignant, benign, in situ, and of unspecified behavior), all new incidence neoplasm patients, exclusively malignant neoplasm patients, and new incidence malignant neoplasm patients. Data on the initial cancer stage were available for calendar year 2020 from about one third of the study's organizations. RESULTS: Although COVID-19 cases fluctuated through 2021, newly diagnosed cancers closely paralleled the prepandemic base year 2019. Similarly, screening for breast, colorectal, and cervical cancers quickly recovered beginning in May 2020 to prepandemic numbers. Preliminary data for the initial cancer stage showed no significant difference ( P > .10) in distribution for breast or colon cancers between 2019 and 2020. CONCLUSION: Although the number of COVID-19 cases fluctuated, the steep declines observed during March and April 2020 in screening for breast and colon cancer and patients with newly diagnosed cancer did not continue through the rest of 2020 and into April 2021. Screening and new incidence cancer numbers quickly rose compared with prepandemic levels. The concern that more patients with advanced-stage cancer would be seen in the months following the drastic dips of March-April 2020 was not realized as the major disruption to normal cancer care was limited to these 2 months.


  • Utility of fertility procedures and prenatal tests to estimate gestational age for live‐births and stillbirths in electronic health plan databases

    by Lockwood G. Taylor, Steven T. Bird, Danijela Stojanovic, Sengwee Toh, Judith C. Maro, Elnara Fazio‐Eynullayeva, Andrew B. Petrone, Rajani Rajbhandari, Susan E. Andrade, Kevin Haynes, et al.

    Purpose: Current algorithms to evaluate gestational age (GA) during pregnancy rely on hospital coding at delivery and are not applicable to non‐live births. We developed an algorithm using fertility procedures and fertility tests, without relying on delivery coding, to develop a novel GA algorithm in live‐births and stillbirths.Methods: Three pregnancy cohorts were identified from 16 health‐plans in the Sentinel System: 1) hospital admissions for live‐birth, 2) hospital admissions for stillbirth, and 3) medical chart‐confirmed stillbirths. Fertility procedures and prenatal tests, recommended within specific GA windows were evaluated for inclusion in our GA algorithm. Our GA algorithm was developed against a validated delivery‐based GA algorithm in live‐births, implemented within a sample of chart‐confirmed stillbirths, and compared to national estimates of GA at stillbirth.Results: Our algorithm, including fertility procedures and 11 prenatal tests, assigned a GA at delivery to 97.9% of live‐births and 92.6% of stillbirths. For live‐births (n = 4 701 207), it estimated GA within 2 weeks of a reference delivery‐based GA algorithm in 82.5% of pregnancies, with a mean difference of 3.7 days. In chart‐confirmed stillbirths (n = 49), it estimated GA within 2 weeks of the clinically recorded GA at delivery for 80% of pregnancies, with a mean difference of 11.1 days. Implementation of the algorithm in a cohort of stillbirths (n = 40 484) had an increased percentage of deliveries after 36 weeks compared to national estimates.Conclusions: In a population of primarily commercially‐insured pregnant women, fertility procedures and prenatal tests can estimate GA with sufficient sensitivity and accuracy for utility in pregnancy studies.


  • Open Access

    Exercise-based cardiac rehabilitation vs. percutaneous coronary intervention for chronic coronary syndrome: impact on morbidity and mortality

    by Benjamin J R Buckley, Iris A de Koning, Stephanie L Harrison, Elnara Fazio-Eynullayeva, Paula Underhill, Hareld M C Kemps, Gregory Y H Lip, Dick H J Thijssen

    Aims: Accumulating evidence questions the clinical value of percutaneous coronary intervention (PCI) for patients with chronic coronary syndrome (CCS). We therefore compare the impact of exercise-based cardiac rehabilitation (CR) vs. PCI in patients with CCS on 18-month mortality and morbidity, and evaluate the effects of combining PCI with exercise-based CR. Methods and results: A retrospective cohort study was conducted in March 2021. An online, real-world dataset of CCS patients was acquired, utilizing TriNetX, a global federated health research network. Patients with CCS who received PCI were first compared with patients who were prescribed exercise-based CR. Second, we compared patients who received both CR + PCI vs. CR alone. For both comparisons, patients were propensity-score matched by age, sex, race, comorbidities, medications, and procedures. We ascertained 18-month incidence of all-cause mortality, rehospitalization, and cardiovascular comorbidity [stroke, acute myocardial infarction (AMI), and new-onset heart failure]. The initial cohort consisted of 18 383 CCS patients. Following propensity score matching, exercise-based CR was associated with significantly lower odds of all-cause mortality [0.37 (95% confidence interval (CI): 0.29–0.47)], rehospitalization [0.29 (95% CI: 0.27–0.32)], and cardiovascular morbidities, compared to PCI. Subsequently, patients that received both CR + PCI did not have significantly different odds for all-cause mortality [1.00 (95% CI: 0.63–1.60)], rehospitalization [1.00 (95% CI: 0.82–1.23)], AMI [1.11 (95% CI: 0.68–1.81)], and stroke [0.71 (95% CI: 0.39–1.31)], compared to CR only. Conclusions: Compared to PCI, exercise-based CR associated with significantly lower odds of 18-month all-cause mortality, rehospitalization, and cardiovascular morbidity in patients with CCS, whilst combining PCI and exercise-based CR associated with lower incident heart failure only.


  • Top Cited Papers
    Open Access

    Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis

    by Stephanie L. Harrison, Elnara Fazio-Eynullayeva, Deirdre A. Lane, Paula Underhill, Gregory Y. H. Lip

    At the beginning of June 2020, there were nearly 7 million reported cases of coronavirus disease 2019 (COVID-19) worldwide and over 400,000 deaths in people with COVID-19. The objective of this study was to determine associations between comorbidities listed in the Charlson comorbidity index and mortality among patients in the United States with COVID-19. A retrospective cohort study of adults with COVID-19 from 24 healthcare organizations in the US was conducted. The study included adults aged 18–90 years with COVID-19 coded in their electronic medical records between January 20, 2020, and May 26, 2020. Results were also stratified by age groups (n = 17,155) were female. The most common comorbidities listed in the Charlson comorbidity index were chronic pulmonary disease (17.5%, n = 5,513) and diabetes mellitus (15.0%, n = 4,710). Multivariate logistic regression analyses showed older age (odds ratio [OR] per year 1.06; 95% confidence interval [CI] 1.06–1.07; p < 0.001), male sex (OR 1.75; 95% CI 1.55–1.98; p < 0.001), being black or African American compared to white (OR 1.50; 95% CI 1.31–1.71; p < 0.001), myocardial infarction (OR 1.97; 95% CI 1.64–2.35; p < 0.001), congestive heart failure (OR 1.42; 95% CI 1.21–1.67; p < 0.001), dementia (OR 1.29; 95% CI 1.07–1.56; p = 0.008), chronic pulmonary disease (OR 1.24; 95% CI 1.08–1.43; p = 0.003), mild liver disease (OR 1.26; 95% CI 1.00–1.59; p = 0.046), moderate/severe liver disease (OR 2.62; 95% CI 1.53–4.47; p < 0.001), renal disease (OR 2.13; 95% CI 1.84–2.46; p < 0.001), and metastatic solid tumor (OR 1.70; 95% CI 1.19–2.43; p = 0.004) were associated with higher odds of mortality with COVID-19. Older age, male sex, and being black or African American (compared to being white) remained significantly associated with higher odds of death in age-stratified analyses. There were differences in which comorbidities were significantly associated with mortality between age groups. Limitations include that the data were collected from the healthcare organization electronic medical record databases and some comorbidities may be underreported and ethnicity was unknown for 24% of participants. Deaths during an inpatient or outpatient visit at the participating healthcare organizations were recorded; however, deaths occurring outside of the hospital setting are not well captured. Identifying patient characteristics and conditions associated with mortality with COVID-19 is important for hypothesis generating for clinical trials and to develop targeted intervention strategies.


  • Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness

    by Sarah K. Dutcher, Elnara Fazio‐Eynullayeva, Efe Eworuke, Amanda Carruth, Elizabeth C. Dee, Michael D. Blum, Michael D. Nguyen, Sengwee Toh, Catherine A. Panozzo, Jennifer G. Lyons

    Purpose To describe utilization of filgrastim and infliximab, the first two products with biosimilars approved in the United States. Methods We identified use of filgrastim (reference, tbo‐filgrastim, and filgrastim‐sndz) and infliximab (reference, infliximab‐dyyb, and infliximab‐abda) in the Sentinel Distributed Database using Healthcare Common Procedure Coding System (HCPCS) codes and National Drug Codes (NDCs) from January 2015 to August 2018. We calculated the proportion of use by code type and assessed uptake over time. We compared baseline patient characteristics and treatment indications. Among patients with >1 exposure episode, we characterized gaps between episodes. Results Use was identified primarily via HCPCS codes (filgrastim: 86.4%‐97.7%; infliximab: 87.8%‐100%) although some was identified via NDCs (filgrastim: 2.2%‐13.5%; infliximab: <0.1%‐6.5%). Filgrastim reference product use declined from 89.4% in January 2015 to 30.3% in June 2018, with corresponding increases in filgrastim‐sndz (0% to 49.3%) and tbo‐filgrastim (10.6% to 20.4%). Infliximab biosimilar uptake was low (9.7% in June 2018). We identified 94 846 filgrastim reference product, 27 143 tbo‐filgrastim, and 38 264 filgrastim‐sndz users. For infliximab, we identified 125 412 reference product, 1034 infliximab‐dyyb, 49 infliximab‐abda, and 4855 undetermined biosimilar users. Patients receiving filgrastim products were largely similar, but differences in age, sex, and indication were observed across infliximab product users. The median exposure episode gap ranged from 1 to 3 days for filgrastim and 48 to 50 days for infliximab. Conclusion Use of biosimilar filgrastim has increased in the United States, but infliximab biosimilar use remains low. Data on identification of biosimilars in claims data and observed gaps between exposure episodes can be used to support drug safety studies of biosimilars.


  • First-Trimester Exposure to Gadolinium-based Contrast Agents: A Utilization Study of 4.6 Million U.S. Pregnancies

    by Steven T. Bird, Kate Gelperin, Leyla Sahin, Karen B. Bleich, Elnara Fazio-Eynullayeva, Corinne Woods, Erica Radden, Patty Greene, Carolyn McCloskey, Tamara Johnson, et al.

    This study identified higher rates of exposure to gadolinium-based contrast agents (GBCAs) during the first few weeks of pregnancy when compared with rates of exposure later in pregnancy, suggestin... BackgroundThe safety of gadolinium-based contrast agent (GBCA) exposure during pregnancy has not been established, and the use of GBCAs during pregnancy is not recommended unless it is essential to...